Mymd Pharmaceuticals (NASDAQ:QCLS) Rating Lowered to “Strong Sell” at Wall Street Zen

Mymd Pharmaceuticals (NASDAQ:QCLS) was downgraded by Wall Street Zen from a “sell” rating to a “strong sell” rating in a report issued on Sunday.

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Mymd Pharmaceuticals in a report on Friday, August 7th. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the company currently has a consensus rating of “Sell”.

Mymd Pharmaceuticals Stock Up 1.4%

Shares of NASDAQ QCLS opened at $2.81 on Friday. The stock has a fifty day moving average of $3.42. Mymd Pharmaceuticals has a 12 month low of $2.50 and a 12 month high of $10.28. The company has a market cap of $11.72 million, a price-to-earnings ratio of -0.14 and a beta of 2.16.

Mymd Pharmaceuticals (NASDAQ:QCLS) last announced its earnings results on Wednesday, August 12th. The company reported ($0.79) earnings per share for the quarter.

About Mymd Pharmaceuticals

MyMD Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on developing novel therapies for immune-related and other serious diseases. The company has worked on product candidates designed to address conditions involving inflammation, immune system dysfunction, and age-related disease processes.

The company’s pipeline has included drug development programs in areas such as autoimmune and inflammatory disorders, with an emphasis on advancing compounds through preclinical and clinical evaluation.